ArticleClinical rheumatology2009
Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus.
Article in Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.Frontiers in immunology · 2018Pooled it
- Retiform purpura and blue toe: an unusual presentation of systemic lupus erythematosus.Clinical rheumatology · 2026Review
- Non-specific cutaneous lupus erythematosus and clinical significance: a literature review.Journal of rheumatic diseases · 2026Review
- Autoantibodies in Systemic Lupus Erythematosus: Diagnostic and Pathogenic Insights.Journal of clinical medicine · 2025Review
- The implication of anti-Ro60 with or without anti-Ro52 antibody in patients with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2025Article
- Article
- Article
- Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.Frontiers in immunology · 2022Article
- Lupus-related vasculitis in a cohort of systemic lupus erythematosus patients.Archives of rheumatology · 2021Article
- Lupus Vasculitis: An Overview.Biomedicines · 2021Review
- Cutaneous vasculitis in lupus treated with IV immunoglobulin.Clinical rheumatology · 2021Article
- Cutaneous vasculitis in SLE.Lupus science & medicine · 2020Article
- Lupus Vasculitis.Current rheumatology reports · 2020Review
- Connective Tissue Disorder-Associated Vasculitis.Current rheumatology reports · 2016Review
- Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.Autoimmune diseases · 2014Review
- Cutaneous vasculitis: a rheumatologist perspective.Current allergy and asthma reports · 2013Review
- Genetics and autoantibodies.Immunologic research · 2013Review
- Clinical and pathological roles of Ro/SSA autoantibody system.Clinical & developmental immunology · 2012Review
- Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus.International journal of rheumatology · 2012Article
- Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon.Clinical rheumatology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease with various clinical and serological manifestations. Previous studies have shown the association of SLE and anti-Ro antibody with a series of clinical manifestations. We investigated this association in Brazilian patients with SLE. Five hundred and nine consecutive patients who fulfilled the revised American College of Rheumatology criteria for the SLE were enrolled in the study from June to December 2007. All patients were from our Service of Rheumatology, School of Medicine, University of São Paulo, Brazil. Frequencies of a series of laboratorial and clinical manifestations were calculated. Anti-Ro antibody was associated to anti-La antibody, female, and cutaneous vasculitis. In multivariate analysis, patients with anti-Ro antibody has 1.63 (95% CI 1.07-2.50) more risk to develop cutaneous vasculitis than patients without this antibody. Our data have demonstrated that anti-Ro antibody is an independent useful serologic marker for cutaneous vasculitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.